Skip to content

Study on the Effect and Mechanism of under Navigation rTMS Regulating Appetite Craving in Overweight Schizophrenia Patients

Study on the Effect and Mechanism of under Navigation rTMS Regulating Appetite Craving in Overweight Schizophrenia Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098545
Enrollment
Unknown
Registered
2025-03-10
Start date
2025-03-15
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Research group:rTMS truly stimulating
Control group:rTMS pseudo stimulation

Sponsors

Suzhou Guangji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.The subject meets the ICD-10 diagnostic criteria for schizophrenia. 2.The subjects are aged between 18 and 45 years old and are right-handed. 3.The total PANSS score of the subject is = 25kg/m^2) after taking antipsychotic medication, and their weight remained stable (+/- 5%) for 4 weeks. 5.Abnormal EEG without clinical significance. 6.Participants and/or their guardians who sign informed consent forms.

Exclusion criteria

Exclusion criteria: 1.Individuals with other severe mental disorders that meet the diagnostic criteria of ICD-10 Individuals with a history of severe head injuries or epileptic seizures Currently, there are other contraindications for the use of cochlear implants, pacemakers, in vivo metal implants, and fMRI or rTMS. 2.Individuals with a history of severe head injuries or epileptic seizures. 3.Currently, there are other contraindications for the use of cochlear implants, pacemakers, in vivo metal implants, and fMRI or rTMS. 4.Individuals who have used weight loss drugs or extremely low calorie diets within the past year, are pregnant or breastfeeding, have suffered from eating disorders or substance dependence Individuals with unstable cardiovascular disease (myocardial infarction or stroke within the past year, heart failure, acute limb ischemia, severe peripheral arterial occlusive disease). 5.Individuals with unstable cardiovascular disease (myocardial infarction or stroke within the past year, heart failure, acute limb ischemia, severe peripheral arterial occlusive disease). 6.Individuals with other potential causes of obesity (hypothyroidism, Cushing's syndrome, hypogonadism, insulinoma). 7.Individuals who have used non convulsive electroconvulsive therapy, tDCS, and other physical therapies within the past six months. 8.Subjects with a history indicating or determined by the researcher to have a significant tendency towards suicide and violence in the current or past 6 months, or those at risk of suicide and violence based on the researcher's clinical assessment, or those deemed unsuitable to participate in the trial by the researcher's assessment. 9.Pregnant, breastfeeding, or planning to conceive during the trial period.

Design outcomes

Primary

MeasureTime frame
Visual analogue scales (VAS) score;Body mass index (BMI);Weight;

Secondary

MeasureTime frame
Total calorie intake (TCI);Peripheral blood exosome levels;Resting state fMRI (rs-fMRI);Personal and social performance scale (PSP) score;Repeat able Battery for the Assessment of Neuropsychologhical Status (RBANS);

Countries

China

Contacts

Public ContactZhang Guangya

Suzhou Guangji Hospital

zgyhjq@163.com+86 189 6211 5017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026